Anthrax - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Anthrax - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anthrax pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Anthrax: Overview
Anthrax is a serious infectious disease caused by gram-positive, rod-shaped bacteria known as Bacillus anthracis. Anthrax can be found naturally in soil and commonly affects domestic and wild animals around the world. Although it is rare in the United States, people can get sick with anthrax if they come in contact with infected animals or contaminated animal products. Anthrax can cause severe illness in both humans and animals.
'Anthrax - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Anthrax pipeline landscape is provided which includes the disease overview and Anthrax treatment guidelines. The assessment part of the report embraces, in depth Anthrax commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anthrax collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Anthrax report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anthrax Emerging Drugs
Further product details are provided in the report
Anthrax: Therapeutic Assessment
This segment of the report provides insights about the different Anthrax drugs segregated based on following parameters that define the scope of the report, such as:
Anthrax: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anthrax therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anthrax drugs.
Anthrax Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Anthrax - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anthrax pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Anthrax: Overview
Anthrax is a serious infectious disease caused by gram-positive, rod-shaped bacteria known as Bacillus anthracis. Anthrax can be found naturally in soil and commonly affects domestic and wild animals around the world. Although it is rare in the United States, people can get sick with anthrax if they come in contact with infected animals or contaminated animal products. Anthrax can cause severe illness in both humans and animals.
'Anthrax - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Anthrax pipeline landscape is provided which includes the disease overview and Anthrax treatment guidelines. The assessment part of the report embraces, in depth Anthrax commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anthrax collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Anthrax R&D. The therapies under development are focused on novel approaches to treat/improve Anthrax.
This segment of the Anthrax report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anthrax Emerging Drugs
- AV 7909: Emergent BioSolutions
- BW 1010: BlueWillow Biologics
Further product details are provided in the report
Anthrax: Therapeutic Assessment
This segment of the report provides insights about the different Anthrax drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Anthrax
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Anthrax: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anthrax therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anthrax drugs.
Anthrax Report Insights
- Anthrax Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Anthrax drugs?
- How many Anthrax drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Anthrax?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anthrax therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Anthrax and their status?
- What are the key designations that have been granted to the emerging drugs?
- Emergent BioSolutions
- BlueWillow Biologics
- Planet Biotechnology
- Altimmune
- GC Pharma
- Crestone Inc
- Greffex
- Hawaii Biotech
- Integrated BioTherapeutics
- Q BioMed
- VLP Biotech
- Porton Biopharma
- Aphios
- DEINOVE
- ENESI Pharma
- Paratek Pharmaceuticals
- Fab’entech
- SporeGen
- AV 7909
- BW 1010
- PBI 220
- NasoShield
- GC-1109
- Research programme: DNA vaccines
- Ba-ISTAb
- MAN 04
- DNV3837
- Nuzyra
Introduction
Executive Summary
Anthrax: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Anthrax – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Anthrax companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Anthrax Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
AV 7909: Emergent BioSolutions
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
BW 1010: BlueWillow Biologics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Anthrax Key Companies
Anthrax Key Products
Anthrax- Unmet Needs
Anthrax- Market Drivers and Barriers
Anthrax- Future Perspectives and Conclusion
Anthrax Analyst Views
Anthrax Key Companies
Appendix
Executive Summary
Anthrax: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Anthrax – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Anthrax companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Anthrax Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
AV 7909: Emergent BioSolutions
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
BW 1010: BlueWillow Biologics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Anthrax Key Companies
Anthrax Key Products
Anthrax- Unmet Needs
Anthrax- Market Drivers and Barriers
Anthrax- Future Perspectives and Conclusion
Anthrax Analyst Views
Anthrax Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Anthrax
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Anthrax
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Anthrax
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Anthrax
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products